TRVN - Spark Newswire

3 minute read

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck

Today, 12:22 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18)

ABBV

10 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 12:22 PM

Wednesday morning, 136 companies reached new 52-week lows.

ADMA

6 minute read

The Daily Biotech Pulse: Moderna’s Vaccine Produces Durable Response Against Variants, FDA Approves Jazz’s Sleep Disorder Drug, Dermata IPO

By Shanthi Rexaline

Today, 12:22 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)

ABVC

3 minute read

12 Health Care Stocks Moving In Thursday’s Intraday Session

By Benzinga Insights

Today, 12:22 PM

ACHL

6 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 12:22 PM

During Thursday's morning trading, 83 companies set new 52-week lows.

ABVC

2 minute read

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights

Today, 12:22 PM

APRE

1 minute read

Trevena: Q2 Earnings Insights

By Benzinga Insights

Today, 12:22 PM

Shares of Trevena (NASDAQ:TRVN) rose 0.7% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 50.00% over the past year to ($0.09), which missed the estimate of ($0.07).

TRVN

15 minute read

Earnings Scheduled For August 12, 2021

By Benzinga Insights

Today, 12:22 PM

Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.

AACG

2 minute read

Trevena Announces Publication Highlighting Risk / Benefit Analysis Of OLINVYK In Pain and Therapy

By Bill Haddad

Today, 12:22 PM

Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the publication of an

TRVN